<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i>-mutant stage II and III colon cancer.

导出 OA

翻译打印收藏纠错

第一作者： Philip D,Dunne

第一单位： Centre for Cancer Research and Cell Biology, Queens's University Belfast, Belfast, UK.

作者： Philip D,Dunne ^[1] ; Helen G,Coleman ^[1] ; Peter,Bankhead ^[2] ; Matthew,Alderdice ^[1] ; Ronan T,Gray ^[1] ; Stephen,McQuaid ^[2] ; Victoria,Bingham ^[1] ; Maurice B,Loughrey ^[1] ; Jacqueline A,James ^[2] ; Amy M B,McCorry ^[1] ; Alan,Gilmore ^[1] ; Caitriona,Holohan ^[1] ; Dirk,Klingbiel ^[1] ; Sabine,Tejpar ^[3] ; Patrick G,Johnston ^[4] ; Darragh G,McArt ^[5] ; Federica,Di Nicolantonio ^[1] ; Daniel B,Longley ^[1] ; Mark,Lawler ^[6]

作者单位： Centre for Cancer Research and Cell Biology, Queens's University Belfast, Belfast, UK. ^[1] Centre for Public Health, Queens's University Belfast, Belfast, UK. ^[2] SAKK Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland. ^[3] SIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, University of Lausanne, Lausanne, Switzerland. ^[4] Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. ^[5] University of Turin, Department of Oncology, Candiolo, Turin, Italy. ^[6] Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Turin, Italy. ^[7]

关键词 Bcl-xL colon cancer gene expression profiling molecular stratification relapse risk

DOI 10.18632/oncotarget.24481

PMID 29568398

发布时间 2024-02-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交